Quantcast

Latest NF-κB Stories

2011-04-19 22:59:38

Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen. Their findings, published in the April issue of the Journal for Clinical Investigation, show how this combination approach kills tumor cells in both mouse models of glioblastoma and human...

07c605cfe9cf2854ff18c15b2aa8389a1
2011-03-24 05:40:00

Scientists reported on Wednesday that they have sequenced the entire genetic code of 38 multiple myeloma patients, and have uncovered the most likely genetic causes of the aggressive blood cancer. The work, carried out by 21 institutions in the U.S. and Canada, offers the most comprehensive picture to date of the full genetic blueprint of multiple myeloma, and provides new and unexpected insights into the events that lead to the disease. "For the first time, we are able to see on a molecular...

2011-02-09 10:00:00

GLEN ALLEN, Va., Feb. 9, 2011 /PRNewswire/ -- Rock Creek Pharmaceuticals, a subsidiary of Star Scientific, Inc. (Nasdaq: CIGX) announced that on February 4 a provisional patent application was filed with the Patent and Trademark Office ("PTO") for administering a pure form of a single isomer of anatabine, "S-(-)anatabine". This isomer can be administered in a composition containing a therapeutically effective dose of anatabine to treat chronic low-level inflammation. Low-level chronic...

2011-01-05 09:04:37

(Ivanhoe Newswire) -- The deletion of a gene called NFKBIA may cause glioblastoma, the most common and malignant brain cancer. Researchers at the Stanford University School of Medicine recently discovered that the deletion of this gene, which is known to promote tumor development and resistance to therapy, was present in one out of every four glioblastoma cases. When NFKBIA is deleted, certain biochemical processes occur with striking similarity to an onset of glioblastoma, which often...

2010-12-23 16:54:43

A study fast-tracked for online publication Dec. 22 in the New England Journal of Medicine has identified an important gene deletion in up to one of every four cases of glioblastoma, the most common adult brain cancer. This deletion contributes to tumor development, promotes resistance to therapy and considerably worsens a patient's survival prospects. The deletion of the gene, known as NFKBIA, triggers biochemical processes similar to those resulting from a better-known aberration common in...

2010-12-15 15:04:40

Their animal study is the first to show that shutting down breast inflammation stops cancer onset and progression It took 12 years and a creation of a highly sophisticated transgenic mouse, but researchers at Kimmel Cancer Center at Jefferson have finally proven a long suspected theory: Inflammation in the breast is key to the development and progression of breast cancer. In the December 15 issue of Cancer Research, the scientists say they can now definitively show that an inflammatory...

2010-12-14 20:23:46

Researchers at the Andalusian Institute for Molecular Biology and Regenerative Medicine (CABIMER) and the University of Granada found that cFLIP "“an inhibitor of death ligand-induced apoptosis"“ is not only essential in breast tumor cells resistance to TRAIL treatments (a death ligand with a potent therapeutic potential against cancer), but this protein is also key to the survival of such cancer cells. Researchers proved that a variation in the expression of this protein may lead...

2010-12-06 07:00:00

SAN DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology (ASH), to be held on December 4-7 in Orlando, FL, the company announced today. Kenna Anderes, VP Cancer Biology at Cylene, will discuss research on targeting CK2, a protein kinase that is essential for the progression of multiple myeloma but that has not been...

2010-11-16 07:00:00

SAN DIEGO, Nov. 16, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. will present advances in the development of their first-in-class, CK2 inhibitor CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, to be held on November 16-19 in Berlin, Germany. CX-4945 is the first and only CK2 inhibitor to have entered clinical trials and represents an exciting new approach for the treatment for many different cancers. Three poster presentations will reveal...

2010-11-04 01:11:55

Proteasome inhibitor reduces inflammation and promotes bone healing in arthritis models A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.